NXL-004
/ NeuExCell Therap
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
April 25, 2024
NXL-004: A novel trans-differentiation therapy for glioblastoma treatment.
(ASCO 2024)
- "Preclinical studies of NXL-004 have demonstrated that this intervention effectively reprograms tumor cells, downregulating glial cell- and tumor-related gene expression, while concurrently upregulating neuron-related gene expression. The induced differentiation towards non-dividing neurons results in significant inhibition of tumor cell proliferation, substantial reductions in tumor volume and prolonged survival in GBM-bearing mice. Additionally, NXL-004 has exhibited a favorable safety profile in toxicity studies in rats and non-human primates."
Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor • NEUROD1
March 21, 2024
NeuExcell Therapeutics Announces Successful Dosing of First Patient by NeuroD1 Gene Therapy
(PRNewswire)
- "NeuExcell Therapeutics...announces the successful dosing of the first patient with the first-in-class NeuroD1 gene therapy product NXL-004. This milestone represents significant progress in the development of new treatment for malignant glioma patients. Led by Professor Yulun Huang and his team at the Fourth Affiliated Hospital of Soochow University in Suzhou, China, the investigator-initiated trial (IIT) will evaluate the safety and tolerability of NeuExcell's AAV-NeuroD1 gene therapy product NXL-004 in patients with glioblastoma."
Trial status • Glioblastoma
December 18, 2023
NeuExcell’s AAV Gene Therapy for Malignant Glioma Granted Orphan Drug Designation by FDA
(PRNewswire)
- "On December 7, 2023, the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation ('ODD') to NXL-004, an investigational AAV gene therapy product being developed by NeuExcell Therapeutics Inc. ('NeuExcell'), for the treatment of malignant glioma. This is the world's first AAV gene therapy product for malignant glioma to receive FDA ODD designation....NeuExcell's lead clinical programs include...GBM, all expected to enter the clinic in 2024..."
New trial • Orphan drug • Brain Cancer • CNS Tumor • Glioma • Oncology • Solid Tumor
1 to 3
Of
3
Go to page
1